Amplio Pharma now planning a phase 2a study after NovoBioJect raised intracellular active methotrexate levels by 38%.
|Articles|July 19, 2022
Rheumatoid Arthritis Quiz: Cancer and RA Treatment
Author(s)Ingrid Torjesen
Patients with rheumatoid arthritis (RA) have a higher risk of cancer, but does treatment of rheumatoid arthritis affect that risk? Test your knowledge with this quiz.
Advertisement
Is the following statement true or false?
Neither tumor necrosis factor (TNF) inhibitors nor non-TNF inhibitor biologic disease-modifying antirheumatic drugs (bDMARDs) increase the risk of lymphoma in patient with rheumatoid arthritis.
Advertisement
Related to this article
The EC approved upadacitinib for active polyarticular JIA in children 2 years and older, based on phase 1 SELECT-YOUTH efficacy and safety data.
August 2026 rheumatology highlights include FDA approval of brepocitinib for dermatomyositis and garetosmab-grts for FOP, and new trial data.
In RA-BRIDGE and RA-BRANCH, baricitinib failed to demonstrate VTE noninferiority in patients with RA enriched for thromboembolic risk factors.
A Phase 2a basket trial produced ACR50 responses in 71% of refractory RA patients at 6 months.
Advertisement
Advertisement